About Adaptimmune Therapeutics plc American Depositary Shares
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Market Cap
$0.06B
Employees
506
Listed Since
May 6, 2015
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Website
www.adaptimmune.comPhone
44 1235 430000
Headquarters
60 JUBILEE AVENUE
ABINGDON, OXFORDSHIRE, X0 OX14 4RX
CIK
0001621227